7-(2-(3-hydroxy-4-phenyl-butyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid | 352423-05-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7-(2-(3-hydroxy-4-phenyl-butyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid
• 英文别名: 7-[2-(3-Hydroxy-4-phenylbutyl)-5-oxopyrrolidin-1-yl]heptanoic acid
• CAS: 352423-05-3
• 化学式: C₂₁H₃₁NO₄
• 分子量: 361.481
• InChiKey: WMEUGWYECRHASZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  26
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• EP4 receptor selective agonists in the treatment of osteoporosis
  申请人：——

  公开号：US20010047105A1

  公开（公告）日：2001-11-29

  This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. This invention is especially directed to those methods wherein the EP4 receptor selective agonist is a compound of Formula I: 1 wherein the variables are as defined in the specification.

  这项发明涉及治疗低骨密度等病症的方法，特别是骨质疏松症、脆弱、骨折、骨缺陷、儿童特发性骨质流失、牙槽骨流失、下颌骨流失、骨折、骨切术、与牙周炎相关的骨流失或假体生长的方法，包括给予EP4受体选择性前列腺素激动剂。这项发明特别涉及EP4受体选择性激动剂为Formula I中的化合物的方法：1其中变量如规范中所定义。
• Treatment of osteoporsis with EP2/EP4 receptor selective agonists
  申请人：——

  公开号：US20010056060A1

  公开（公告）日：2001-12-27

  This invention is directed to methods and pharmaceutical compositions comprising prostaglandin agonists which are userful to prevent bone loss, restore or augment bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass, such as osteoporosis, and/or bone defects in vertebrates, and particularly mammals, including humans. This invention specifically relates to methods and pharmaceutical compositions comprising combinations of EP 2 receptor selective agonists and EP 4 receptor selective agonists and to methods and pharmaceutical compositions comprising agents which are agonists for both the EP 2 receptor and the EP 4 receptor.

  本发明涉及使用前列腺素激动剂的方法和制药组合物，其有助于预防骨质流失，恢复或增加骨量，并增强骨愈合，包括治疗低骨量症状，如骨质疏松症和/或脊椎动物中的骨缺陷，特别是哺乳动物，包括人类。本发明具体涉及包含EP2受体选择性激动剂和EP4受体选择性激动剂的方法和制药组合物，以及包含同时是EP2受体和EP4受体激动剂的药物。
• Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
  申请人：——

  公开号：US20030176479A1

  公开（公告）日：2003-09-18

  The present invention is directed to methods for treating liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension, comprising administering to the patient in need thereof a therapeutically effective amount of a selective EP 4 receptor agonist of the Formulae 1 wherein the variables A, B, Q, ═U, and R 2 for Formula l; and the variables Ar, ═M, ═N, R, W, and Z for Formula II are as defined in the specification.

  本发明涉及治疗肝功能衰竭、动脉导管未开放、青光眼或眼压增高的方法，包括向需要治疗的患者施用公式1中选择性EP4受体激动剂的治疗有效剂量，其中公式1中的变量A、B、Q、═U和R2；以及公式II中的变量Ar、═M、═N、R、W和Z在规范中定义。
• Treatment of osteoporosis with EP2/EP4 receptor selective agonists
  申请人：Pfizer Products Inc.

  公开号：EP1121939A2

  公开（公告）日：2001-08-08

  This invention is directed to methods and pharmaceutical compositions comprising prostaglandin agonists which are useful to prevent bone loss, restore or augment bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass, such as osteoporosis, and/or bone defects in vertebrates, and particularly mammals, including humans, This invention specifically relates to methods and pharmaceutical compositions comprising combinations of EP2 receptor selective agonist and EP4 receptor selective agonists and to methods and pharmaceutical compositions comprising agents which are agonists for both the EP2 receptor and the EP4 receptor.

  本发明涉及包含前列腺素激动剂的方法和药物组合物，前列腺素激动剂可用于防止骨质流失、恢复或增强骨量以及促进骨愈合，包括治疗脊椎动物的低骨量病症，如骨质疏松症和/或骨缺损、本发明特别涉及由 EP2 受体选择性激动剂和 EP4 受体选择性激动剂组合而成的方法和药物组合物，以及由同时为 EP2 受体和 EP4 受体激动剂的制剂组成的方法和药物组合物。
• Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
  申请人：Pfizer Products Inc.

  公开号：EP1132086A2

  公开（公告）日：2001-09-12

  This invention is directed to methods and compositions of teating acute or chronic renal failure or dysfunction, or conditions caused thereby comprising administering prostaglandin agonists, which ae EP4 receptor selective prostaglandin agonists.

  本发明涉及治疗急性或慢性肾功能衰竭或功能障碍或由其引起的病症的方法和组合物，包括施用前列腺素激动剂（EP4 受体选择性前列腺素激动剂）。